Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT is a gene therapy-focused biotech company developing therapeutic candidates using its proprietary vector platform (lead programs 4D-150 and 4D-710).
|
$519.76M |
$10.77
-4.01%
|
|
CMPX
Compass Therapeutics, Inc.
Compass Therapeutics is an oncology-focused biotech developing cancer therapies, anchoring its business in oncology.
|
$517.18M |
$3.79
+1.20%
|
|
MNPR
Monopar Therapeutics Inc.
MNPR is pursuing oncology-focused assets (MNPR-101 radiopharmaceuticals) and monoclonal antibody–based therapies, aligning with Biotech - Oncology.
|
$513.68M |
$82.62
-1.64%
|
|
ORGO
Organogenesis Holdings Inc.
ReNu knee osteoarthritis program is a cell therapy (biotech) product, aligning with Biotech - Cell Therapy.
|
$507.41M |
$3.90
-2.62%
|
|
BCYC
Bicycle Therapeutics plc
Company's core focus is oncology with Bicycle Molecule platform and multiple lead oncology programs.
|
$503.17M |
$6.96
-4.13%
|
|
LXRX
Lexicon Pharmaceuticals, Inc.
Lexicon's pipeline includes oral small-molecule therapeutics pilavapadin (LX9211) and LX9851; these are oral small-molecule drugs, a major product category in their portfolio.
|
$493.92M |
$1.34
-1.10%
|
|
FULC
Fulcrum Therapeutics, Inc.
Fulcrum's lead asset pociredir is an oral small molecule therapeutic intended to induce HbF in SCD.
|
$487.91M |
$8.46
-6.15%
|
|
NMRA
Neumora Therapeutics, Inc. Common Stock
Company focuses on neuropsychiatric drug development, including navacaprant for major depressive disorder, aligning with Neuropsychiatric Drug Development.
|
$486.86M |
$2.92
-2.99%
|
|
RAPT
RAPT Therapeutics, Inc.
RAPT's pipeline includes oncology-focused assets under Biotech - Oncology (tivumecirnon) and broader oncology immunotherapy focus.
|
$485.33M |
$28.23
-3.80%
|
|
ETON
Eton Pharmaceuticals, Inc.
KHINDIVI (ET-400), ET-600, ET-700, and ET-800 involve oral/ready formulations (e.g., desmopressin, hydrocortisone, zinc) consistent with the Oral Small Molecule Therapeutics category.
|
$481.64M |
$18.43
+2.62%
|
|
CGEM
Cullinan Therapeutics, Inc.
Cullinan develops bispecific antibodies (CD19xCD3 and BCMAxCD3) as core assets.
|
$460.90M |
$7.50
-3.91%
|
|
PRTC
PureTech Health plc
Glyph platform is a drug-delivery technology enabling oral administration of therapies.
|
$457.82M |
$17.68
+3.97%
|
|
OCGN
Ocugen, Inc.
Ocugen's modifier gene therapy platform and lead retinal candidates (OCU400/OCU410) are gene therapy products targeting vision disorders.
|
$449.73M |
$1.46
-5.52%
|
|
LCTX
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics' core business is developing allogeneic cell therapy platforms and products (OpRegen, OPC1, ReSonance ANP1).
|
$447.58M |
$1.82
-7.14%
|
|
NGNE
Neurogene Inc.
NGNE directly develops gene therapy candidates (NGN-401) and uses a gene therapy platform, matching Biotech - Gene Therapy.
|
$442.98M |
$32.23
+3.75%
|
|
OMER
Omeros Corporation
Narsoplimab and zaltenibart OMS906 are monoclonal antibody therapeutics, a core product class for Omeros.
|
$420.11M |
$6.93
-3.35%
|
|
AUTL
Autolus Therapeutics plc
Core product: obe-cel CAR-T cell therapy (cell therapy) for rr B-ALL.
|
$415.18M |
$1.44
-8.01%
|
|
ADCT
ADC Therapeutics S.A.
ADCT's lead product ZYNLONTA is an antibody-drug conjugate (ADC), directly aligning with the Antibody-Drug Conjugates category.
|
$414.57M |
$4.05
-2.99%
|
|
EOLS
Evolus, Inc.
Evolus directly produces botulinum toxin type A product (Jeuveau) used for cosmetic neuromodulation, a core injectable aesthetic treatment.
|
$412.00M |
$6.48
+1.41%
|
|
BNTC
Benitec Biopharma Inc.
BB-301 is an AAV-based gene therapy leveraging gene silencing and wildtype replacement, aligning with Gene Therapy.
|
$406.02M |
$15.65
-1.29%
|
|
SRDX
Surmodics, Inc.
The company provides proprietary drug-delivery platform technologies used on medical devices (SurVeil DCB) and related platforms.
|
$404.96M |
$27.64
-2.38%
|
|
SLDB
Solid Biosciences Inc.
Solid Biosciences is developing viral-vector gene therapies (SGT-3.00, SGT-212, SGT-501) and related products, fitting squarely under Biotech - Gene Therapy.
|
$403.08M |
$4.44
-14.62%
|
|
TOI
The Oncology Institute, Inc.
Radiopharmaceutical therapy is a modality offered in their oncology practice.
|
$400.66M |
$4.26
-5.01%
|
|
KMDA
Kamada Ltd.
Biosimilar product distribution is a key existing business line for Kamada's expanded portfolio.
|
$396.03M |
$6.71
-2.54%
|
|
YMAB
Y-mAbs Therapeutics, Inc.
Company operates oncology-focused biotechnology with immunotherapy assets.
|
$389.89M |
$8.61
|
|
ITOS
iTeos Therapeutics, Inc.
iTeos Therapeutics is a biotech company focused on oncology, developing cancer immunotherapies.
|
$388.48M |
$10.15
|
|
RCKT
Rocket Pharmaceuticals, Inc.
Direct gene therapy platform encompassing ex vivo LV and in vivo AAV modalities.
|
$383.55M |
$3.35
-5.76%
|
|
AHG
Akso Health Group
Cancer therapy/oncology biotech focus and planned oncology centers.
|
$383.46M |
$1.60
|
Showing page 11 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
